Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
1.850
+0.050 (2.78%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Serina Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Steven Ledger |
Contact Details
Address: 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States | |
| Phone | 256 327 9630 |
| Website | serinatherapeutics.com |
Stock Details
| Ticker Symbol | SER |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001708599 |
| CUSIP Number | 81751A108 |
| ISIN Number | US81751A1088 |
| Employer ID | 82-1436829 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven A. Ledger | Chief Executive Officer and Director |
| Dr. Balkrishan Gill Ph.D. | Executive Co-Chairman of the Board |
| Dr. J. Milton Harris Ph.D. | Co-Founder, Director Emeritus and Chair of Scientific Advisory Board |
| Gregory S. Curhan | Chief Financial Officer |
| Dr. Srini Tenjarla | Senior Vice President of Chemistry, Manufacturing and Controls and Formulation |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |
| Dr. Joshua Thomas Ph.D. | Head of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2026 | 8-K | Current Report |
| Apr 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2026 | 10-K/A | [Amend] Annual report |
| Mar 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 23, 2026 | 8-K | Current Report |
| Feb 13, 2026 | EFFECT | Notice of Effectiveness |